CClinicalTrials.gg
CompletedNCT05017415Updated Sep 19, 2024

Applicability of Uroflowmetry in Children with Cerebral Palsy

An interventional study of uroflow measurement and Bladder ultrasound in Cerebral Palsy and Lower Urinary Tract Symptoms, sponsored by University Hospital, Ghent. Completed at 1 site in Belgium. Open to participants aged 5 Years to 12 Years. Per ClinicalTrials.gov, last updated 2024-09-19.

Sponsored by University Hospital, Ghent · Not applicable, Interventional, and Screening

Phase
Not applicable
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
5 Years to 12 Years
Sex
All
01

Study summary

Until now, the use of invasive urodynamics with use of catheters is still the gold standard for lower urinary tract evaluation in subjects with CP. This suggests a psychological and physical impact of invasive urodynamics in subjects with CP and further demonstrates the need to avoid standard use of invasive urodynamics in children and adults with CP.

The current study will evaluate usefulness of uroflowmetry, correlation between uroflowmetry parameters and different lower urinary tract symptoms will be investigated. Secondly, results of uroflowmetry indicating possible vulnerability of the upper urinary tract will be defined.

Read the detailed description

A cross-sectional case-control study comparing children with CP and LUTS and children with CP without LUTS will be conducted with the primary objective to investigate correlation between uroflowmetry parameters and different LUTS.

Children will be evaluated with uroflowmetry and subsequent post void residual measurement and the validated vancouver symptom score for dysfunctional elimination syndrome.

02

Conditions studied

  • Cerebral Palsy
  • Lower Urinary Tract Symptoms

Keywords

  • cerebral palsy
  • lower urinary tract symptoms
  • incontinence
  • uroflow measurement
03

In context

Paralysis

750 studies on the registry are indexed under Paralysis; 133 are open to participants now.

This study's enrollment of 56 is above the median of 30 across 537 interventional studies indexed under Paralysis.

Browse Paralysis studies →

Lead sponsor

University Hospital, Ghent is the lead sponsor of 665 studies on the registry; 156 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 4 (80%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Diagnosis of cerebral palsy
  • Dutch or French speaking child and parent

Exclusion criteria

Exclusion Criteria:

  • History of urological surgery
05

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Standard toilet chair (hip angle 90°)

    uroflow measurement with subsequent post void residual measurement, conducted on a standard toilet chair.

    Device: uroflow measurement · Device: Bladder ultrasound

  • Experimental
    Toilet chair with decreased hip angle

    uroflow measurement with subsequent post void residual measurement, conducted on a toilet chair with decreased hip angle.

    Device: uroflow measurement · Device: Bladder ultrasound

Interventions

  • Deviceuroflow measurement

    Non-invasive urodynamic measurement wireless uroflowmeter UROCAP™ IV, Goby System Laborie

    Also known as: uroflowmetry

  • DeviceBladder ultrasound

    Ultrasound of post void residual urine bladderscan CUBEscan BioCon 700

    Also known as: US

06

What researchers measure

Primary outcomes

  1. Amount of pathological uroflow patterns - Qualitative assessment

    Interpretation by pediatric urologist following ICCS classification Measured during uroflowmetry

    Time frame: During cross-sectional testing

  2. Amount of pathological uroflow patterns - Quantitative assessment

    Interpretation using Flow index methodology Measured during uroflowmetry

    Time frame: During cross-sectional testing

  3. Maximal flow

    Measured during uroflowmetry Qmax (mililitres/seconds

    Time frame: During cross-sectional testing

Secondary outcomes

  1. Influencing factors for uroflow measurement

    * Functional impairment of the child * hip angle * Vancouver symptom score for dysfunctional elimination syndrome

    Time frame: During cross-sectional testing

  2. Voided volume

    Measured during uroflowmetry mililitres Percentage of expected bladder capacity

    Time frame: During cross-sectional testing

  3. Post void residual urine

    Measured with CUBEscan BioCon 700 mililiters Percentage of voided volume

    Time frame: During cross-sectional testing

07

Study locations

1 site
  • Ghent University Hospital
    Ghent, Flanders 9000, Belgium
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05017415
Lead sponsor
University Hospital, Ghent
Collaborators
University Ghent
Responsible party
Sponsor
First posted
Aug 23, 2021
Start date
Oct 14, 2021
Primary completion
Jun 30, 2023
Completion
Jun 30, 2023
Last update
Sep 19, 2024

Study contacts

Bieke Samijn, dr.
principal investigator · Ghent University Hospital/Ghent University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion